Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/50161
Title: Composite anatomical-clinical-molecular prognostic model in nonsmall cell lung cancer
Authors: López-Encuentra, A.
López-Ríos, F.
Conde, E.
García-Luján, R.
Suárez-Gauthier, A.
Mañes, N.
Renedo, G.
Duque-Medina, J. L.
García-Lagarto, E.
Rami-Porta, R.
González-Pont, G.
Astudillo-Pombo, J.
Maté-Sanz, J. L.
Freixinet, J. 
Romero-Saavedra, T.
Sánchez-Céspedes, M.
Gómez de la Camara, A.
UNESCO Clasification: 32 Ciencias médicas
320101 Oncología
Keywords: Ki67cell proliferation index
Lung cancer
Mammalian target of rapamycin
Prognosis
Staging
Issue Date: 2011
Journal: European Respiratory Journal 
Abstract: The objective of the present study was to elaborate a survival model that integrates anatomic factors, according to the 2010 seventh edition of the tumour, node and metastasis (TNM) staging system, with clinical and molecular factors. Pathologic TNM descriptors (group A), clinical variables (group B), laboratory parameters (group C) and molecular markers (tissue microarrays; group D) were collected from 512 early-stage nonsmall cell lung cancer (NSCLC) patients with complete resection. A multivariate analysis stepped supervised learning classification algorithm was used. The prognostic performance by groups was: areas under the receiver operating characteristic curve (C-index): 0.67 (group A), 0.65 (Group B), 0.57 (group C) and 0.65 (group D). Considering all variables together selected for each of the four groups (integrated group) the C-index was 0.74 (95% CI 0.70-0.79), with statistically significant differences compared with each isolated group (from p = 0.006 to p < 0.001). Variables with the greatest prognostic discrimination were the presence of another ipsilobar nodule and tumour size > 3 cm, followed by other anatomical and clinical factors, and molecular expressions of phosphorylated mammalian target of rapamycin (phospho-mTOR), Ki67cell proliferation index and phosphorylated acetyl-coenzyme A carboxylase. This study on early-stage NSCLC shows the benefit from integrating pathological TNM, clinical and molecular factors into a composite prognostic model. The model of the integrated group classified patients with significantly higher accuracy compared to the TNM 2010 staging.
URI: http://hdl.handle.net/10553/50161
ISSN: 0903-1936
DOI: 10.1183/09031936.00028610
Source: European Respiratory Journal[ISSN 0903-1936],v. 37, p. 136-142 (Enero 2011)
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

11
checked on Aug 14, 2022

Page view(s)

14
checked on Jun 12, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.